Michael Siatkowski

Wallace, D. K., Kraker, R., Freedman, S., Crouch, E., Bhatt, A., Hartnett, E., et al. (2020). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. Jama Ophthalmology, 138(6), 698-701. 10.1001/jamaophthalmol.2020.0334 (Original work published 2020)
View
Wallace, D. K., Kraker, R., Freedman, S., Crouch, E., Hutchinson, A., Bhatt, A., et al. (2017). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. Jama Ophthalmology, 135(6), 654-656. 10.1001/jamaophthalmol.2017.1055 (Original work published 2017)
View
Siatkowski, M., Good, W. V., Summers, G., Quinn, G. E., & Tung, B. (2013). Clinical characteristics of children with severe visual impairment but favorable retinal structural outcomes from the Early Treatment for Retinopathy of Prematurity (ETROP) study. Journal Of The American Association For Pediatric Ophthalmology And Strabismus (J Aapos), 17(2), 129-34. 10.1016/j.jaapos.2012.10.022 (Original work published 2013)
View
Good, W. V., Hardy, R. J., Wallace, D. K., Bremer, D. L., Rogers, D., Siatkowski, M., et al. (2012). β-Blocking and racial variation in the severity of retinopathy of prematurity. Archives Of Ophthalmology, 130(1), 117-8. 10.1001/archopht.130.1.117 (Original work published 2012)
View
Davitt, B. V., Dobson, V., Good, W. V., Hardy, R. J., Quinn, G. E., Siatkowski, M., et al. (2005). Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology, 112(9), 1564-8. 10.1016/j.ophtha.2005.03.025 (Original work published 2005)
View